- Home
- SAFT vs DYN Comparison
SAFT vs DYN Comparison
Compare SAFT & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFT
- DYN
- Stock Information
- Founded
- SAFT 1979
- DYN 1984
- Country
- SAFT United States
- DYN United States
- Employees
- SAFT N/A
- DYN N/A
- Industry
- SAFT Property-Casualty Insurers
- DYN Medicinal Chemicals and Botanical Products
- Sector
- SAFT Finance
- DYN Health Care
- Exchange
- SAFT Nasdaq
- DYN Nasdaq
- Market Cap
- SAFT 1.2B
- DYN 1.3B
- IPO Year
- SAFT N/A
- DYN 2020
- Fundamental
- Price
- SAFT $81.84
- DYN $12.70
- Analyst Decision
- SAFT
- DYN Strong Buy
- Analyst Count
- SAFT 0
- DYN 13
- Target Price
- SAFT N/A
- DYN $45.92
- AVG Volume (30 Days)
- SAFT 44.3K
- DYN 2.5M
- Earning Date
- SAFT 05-07-2025
- DYN 05-08-2025
- Dividend Yield
- SAFT 4.40%
- DYN N/A
- EPS Growth
- SAFT 40.60
- DYN N/A
- EPS
- SAFT 4.90
- DYN N/A
- Revenue
- SAFT $1,153,213,000.00
- DYN N/A
- Revenue This Year
- SAFT N/A
- DYN N/A
- Revenue Next Year
- SAFT N/A
- DYN N/A
- P/E Ratio
- SAFT $16.76
- DYN N/A
- Revenue Growth
- SAFT 17.03
- DYN N/A
- 52 Week Low
- SAFT $70.71
- DYN $6.36
- 52 Week High
- SAFT $90.00
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- SAFT 56.01
- DYN 60.66
- Support Level
- SAFT $80.11
- DYN $11.51
- Resistance Level
- SAFT $83.77
- DYN $12.34
- Average True Range (ATR)
- SAFT 1.72
- DYN 0.75
- MACD
- SAFT -0.08
- DYN 0.02
- Stochastic Oscillator
- SAFT 56.38
- DYN 86.93
About SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.